Results 71 to 80 of about 10,805 (242)

FGF2 Attenuated Inflammation-Mediated Cardiac Damage: A Novel Mechanistic Insight into the AMPK–FUNDC1–Mitophagy

Research
Septic cardiomyopathy, a severe complication of sepsis, is characterized by high morbidity and mortality rates, and its effective management remains an important challenge.
Pingjun Zhu, Xi Wang, Xinjie Han, Yan Wang, Yongkai Ding, Min Zhu, Xin Zhang, Qian Xu, Yukun Li, Zhongxuan Li, Zhi Lu, Qi Zhang, Yan Yin, Guogang Xu, Yingzhen Du   +14 more
doaj   +1 more source

Forecasting heart failure: Seasonal alignment of heart failure outcomes in New York

ESC Heart Failure, Volume 12, Issue 2, Page 819-831, April 2025.
Abstract Background Seasonal variations have been observed in heart failure (HF) hospitalization. Numerous explanatory mechanisms have been proposed, but no prior studies have examined potential contributors directly. Our objective was to identify specific factors that could contribute to seasonal variability using a large longitudinal dataset of HF ...
Prerna Gupta, Ellen Brinza, Prateeti Khazanie, Pamela N. Peterson, P Michael Ho, David P. Kao   +5 more
wiley   +1 more source

Role of complement C5a and histones in septic cardiomyopathy

Molecular Immunology, 2018
Polymicrobial sepsis (after cecal ligation and puncture, CLP) causes robust complement activation with release of C5a. Many adverse events develop thereafter and will be discussed in this review article. Activation of complement system results in generation of C5a which interacts with its receptors (C5aR1, C5aR2).
Fatemeh Fattahi, Lynn M. Frydrych, Guowu Bian, Miriam Kalbitz, Todd J. Herron, Elizabeth A. Malan, Matthew J. Delano, Peter A. Ward   +7 more
openaire   +3 more sources

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Transesophageal echocardiography-guided anesthetic management of a patient with dilated cardiomyopathy, severe heart failure, and septic shock: a case report

Frontiers in Medicine
Perioperative management of severe dilated cardiomyopathy (DCM) with markedly reduced left ventricular ejection fraction (LVEF) is particularly complex, especially when complicated by septic shock, as standard resuscitative measures may trigger acute ...
Lixin Chen, Lixin Chen, Jianbin Li, Jianbin Li, Mintai Gao, Mintai Gao, Danjun Zhu, Danjun Zhu, Ruiyu Li, Ruiyu Li, Ganghua Yang, Ganghua Yang   +11 more
doaj   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

Pathophysiology, echocardiographic evaluation, biomarker findings, and prognostic implications of septic cardiomyopathy: a review of the literature

Critical Care, 2018
Background Sepsis is a common condition encountered by emergency and critical care physicians, with significant costs, both economic and human. Myocardial dysfunction in sepsis is a well-recognized but poorly understood phenomenon.
Robert R. Ehrman, Ashley N. Sullivan, Mark J. Favot, Robert L. Sherwin, Christian A. Reynolds, Aiden Abidov, Phillip D. Levy   +6 more
doaj   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Myeloid deficiency of Z‐DNA binding protein 1 restricts septic cardiomyopathy via promoting macrophage polarisation towards the M2‐subtype

Clinical and Translational Medicine
Background Septic cardiomyopathy is a frequent complication in patients with sepsis and is associated with a high mortality rate. Given its clinical significance, understanding the precise underlying mechanism is of great value.
Yifan Shi, Lu He, Jie Ni, Yuyuan Zhou, Xiaohua Yu, Yao Du, Yang Li, Xi Tan, Yufang Li, Xiaoying Xu, Si Sun, Lina Kang, Biao Xu, Jibo Han, Lintao Wang   +14 more
doaj   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source